These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 12837139

  • 1. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
    Kinon BJ, Stauffer VL, McGuire HC, Kaiser CJ, Dickson RA, Kennedy JS.
    J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
    [Abstract] [Full Text] [Related]

  • 2. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
    Markianos M, Hatzimanolis J, Lykouras L.
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [Abstract] [Full Text] [Related]

  • 4. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.
    Fontaine CS, Hynan LS, Koch K, Martin-Cook K, Svetlik D, Weiner MF.
    J Clin Psychiatry; 2003 Jun; 64(6):726-30. PubMed ID: 12823090
    [Abstract] [Full Text] [Related]

  • 5. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S, Zipursky RB, Remington G.
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [Abstract] [Full Text] [Related]

  • 6. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
    Yasui-Furukori N, Saito M, Nakagami T, Sugawara N, Sato Y, Tsuchimine S, Furukori H, Kaneko S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):537-40. PubMed ID: 20170699
    [Abstract] [Full Text] [Related]

  • 7. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR, Taylor CC, Kinon BJ, Breier A.
    Clin Ther; 2000 Sep 16; 22(9):1085-96. PubMed ID: 11048906
    [Abstract] [Full Text] [Related]

  • 8. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H, Slyk MP, Deymann S, Cornacchione MJ.
    J Am Med Dir Assoc; 2003 Sep 16; 4(4):183-8. PubMed ID: 12837138
    [Abstract] [Full Text] [Related]

  • 9. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A.
    Clin Neurol Neurosurg; 2005 Oct 16; 107(6):497-508. PubMed ID: 15922506
    [Abstract] [Full Text] [Related]

  • 10. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
    Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA.
    Psychoneuroendocrinology; 2006 Jun 16; 31(5):577-88. PubMed ID: 16488084
    [Abstract] [Full Text] [Related]

  • 11. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
    Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA.
    J Clin Psychiatry; 2002 May 16; 63(5):408-13. PubMed ID: 12019665
    [Abstract] [Full Text] [Related]

  • 12. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S, Mastwyk M, O'Connor DW, Opie J, Ames D.
    Int J Geriatr Psychiatry; 2003 May 16; 18(5):432-40. PubMed ID: 12766921
    [Abstract] [Full Text] [Related]

  • 13. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
    Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.
    Curr Med Res Opin; 2008 May 16; 24(5):1399-405. PubMed ID: 18397549
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL.
    J Clin Psychiatry; 2003 May 16; 64(5):580-8. PubMed ID: 12755663
    [Abstract] [Full Text] [Related]

  • 15. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.
    Migliardi G, Spina E, D'Arrigo C, Gagliano A, Germanò E, Siracusano R, Diaz FJ, de Leon J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov 13; 33(8):1496-501. PubMed ID: 19706318
    [Abstract] [Full Text] [Related]

  • 16. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
    Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH.
    J Clin Psychiatry; 2001 Nov 13; 62 Suppl 2():28-34. PubMed ID: 11232749
    [Abstract] [Full Text] [Related]

  • 17. Using antipsychotic agents in older patients.
    Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.
    J Clin Psychiatry; 2004 Nov 13; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [Abstract] [Full Text] [Related]

  • 18. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
    Takahashi H, Kamata M, Yoshida K, Ishigooka J, Higuchi H.
    J Clin Psychiatry; 2006 Oct 13; 67(10):1577-82. PubMed ID: 17107250
    [Abstract] [Full Text] [Related]

  • 19. Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
    Verma S, Orengo CA, Kunik ME, Hale D, Molinari VA.
    Int J Geriatr Psychiatry; 2001 Feb 13; 16(2):223-7. PubMed ID: 11241729
    [Abstract] [Full Text] [Related]

  • 20. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F.
    J Clin Psychiatry; 2003 Feb 13; 64(2):134-43. PubMed ID: 12633121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.